Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML).

Trial Profile

Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs AT 406 (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Sep 2012 Planned End Date changed from 1 Apr 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Additional lead trial centre and investigator identified as reported by Memorial Sloan-Kettering Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top